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Abstract
Introduction: Schnitzler Syndrome is an uncommon, inflammatory condition that presents with
a constellation of chronic unremitting urticaria, fever, bone pain, arthralgia or arthritis, and a
monoclonal IgM gammopathy. There is usually neutrophilia and raised inflammatory markers.
Delayed diagnosis is common and treatment often unsuccessful.
Case presentation: We report the case of a 43-year-old caucasian man who presented with
urticaria unresponsive to conventional therapy. There was considerable delay in recognition of this
as Schnitzler Syndrome, and symptoms were unresponsive to conventional immunosuppressive
therapy.
Commencement of anakinra was associated with a rapid and sustained clinical response.
Conclusion: Schnitzler Syndrome is a rare disorder that mimics chronic idiopathic urticaria. This
diagnosis should be considered in patients with urticaria unresponsive to antihistamines and
conventional immunosuppressive therapy. Anakinra is an effective treatment although further
studies are required, to determine long term therapeutic requirements and assess any potential
adverse effects.
Introduction
Chronic idiopathic urticaria (CIU) is a common, benign
condition for which patients are frequently referred to
allergy or dermatology clinics. The investigation and man-
agement of patients with urticaria has recently been
reviewed [1]. The majority of patients presenting with
urticaria do not require extensive laboratory investigation
and their symptoms usually respond to regular oral anti-
histamines, albeit often at high dose. For selected unre-
sponsive patients, the use of immunosuppressive agents is
occasionally required. The case we report initially pre-
sented with an urticarial rash only, but this was later fol-
lowed by the development of fever, arthralgia,
lymphadenopathy and raised inflammatory markers.
Extensive investigation was therefore undertaken and a
provisional diagnosis of Adult Onset Still's Disease
(AOSD) made. However in view of the lack of response to
immunosuppressive treatment and the subsequent dra-
matic response to anakinra, the final diagnosis of Schnit-
zler Syndrome (SS) was established. SS is a rare condition,
with less than 100 cases described. Because of its rarity
and the lack of a specific diagnostic test, it is likely to be
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under diagnosed. This case highlights its importance as a
differential diagnosis of CIU and its apparent exquisite
sensitivity to treatment with anakinra.
Case presentation
A previously well 43-year-old man presented with chronic
urticaria (Figure 1). There was no obvious precipitant
identified from the history, he was systemically well and
investigations including FBP, U&E, LFTs, TFTs, ESR, and
CRP were normal. A polyclonal increase in IgG and IgA
was noted with an associated small (< 1 g/L) IgM kappa
paraprotein. The rash was resistant to conventional treat-
ment with non-sedating antihistamines.
At review, 6 months later, he had developed generalized
fatigue, fever, night sweats, arthralgia, right knee and tib-
ial pain, weight loss and bilateral axillary and inguinal
lymphadenopathy.
Investigations showed a persistent neutrophilia (> 15 ×
109/L) and raised ESR and CRP. Other haematological
indices were within normal limits. A persistent polyclonal
elevation in IgG, A and M was noted, with the IgM kappa
paraprotein increased to 3.3 g/L. Serum ferritin was mildly
elevated (361 μg/L, normal range 18–325). An inflamma-
tory arthritis was suspected, and admission arranged for
further investigation and treatment.
Quotidian spiking fevers (> 38°C) were recorded whilst
an inpatient. Isotope bone scan showed increased tracer
uptake at proximal aspect of right tibia in comparison
with the left. MRI right knee showed non specific marrow
signal change at distal end of femur/proximal tibia. CT
chest, abdomen and pelvis showed florid bilateral axillary
and inguinal lymphadenopathy (Figure 2). Serum anti-
bodies to nuclei, extractable nuclear antigens, double
stranded DNA, cyclic citrullinated peptide, and neu-
trophil cytoplasmic antigens were all negative. Rheuma-
toid factor was negative and serum C3 and C4 levels were
normal. There was a slight elevation in B2 microglobulin
and plasma viscosity, but lymphocyte subsets including
kappa/lambda ratios were normal, and urine analysis was
negative for Bence Jones protein. Serological investiga-
tions for EBV, CMV, HIV, syphilis, hepatitis A, B and C,
Urticarial rash at presentation Figure 1
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borrelia burgdoderi, brucella abortus, chlamydia, Q fever,
mycoplasma, and HHV8 were negative. ASOT was < 200.
Urine cultures for mycobacterium were repeatedly nega-
tive.
Skin biopsy demonstrated an inflammatory infiltrate in
the epidermis, suggestive of either rheumatoid arthritis or
Still's disease. Lymph node biopsy revealed polyclonal
reactive hyperplasia with abundance of plasma cells (Fig-
ure 3). Castleman disease was considered but excluded
after a further biopsy and review by several expert his-
topathologists. Bone marrow biopsy showed reactive
changes only.
Mutations were not found in the coding regions of MVK,
TNFRSF1A, and NLRP3 (previously NALP3/CIAS1) mak-
ing the diagnoses of Hyper IgD syndrome, TNF receptor
associated periodic syndrome (TRAPS), and Muckle
Wells/Familial Cold Urticaria all unlikely.
A tentative diagnosis of Adult Onset Still's Disease
(AOSD) was made. Trials of etoricoxib, and subsequent
oral prednisolone (40 mg daily) with methotrexate (20
mg weekly) were however ineffective. Two cycles of
pulsed methylprednisolone (250 mg and 500 mg)
resulted in transient improvement in both symptoms and
inflammatory markers over the initial 36 hours, but symp-
toms returned on completion of cycle. A trial of inflixi-
mab (5 mg/kg) resulted in a paradoxical exacerbation
with night sweats, fever, arthralgia and urticaria.
Symptoms and signs persisted over the next year despite
symptomatic treatment. The patient was severely disabled
by these and only able to work part time.
Four years after initial presentation, a further trial of pred-
nisolone (60 mg/day) was commenced. 48 hours after
commencement of treatment there was almost complete
resolution of symptoms. Initial CRP (149 mg/L) fell to
10.8 mg/L after 13 days treatment. Azathioprine was com-
menced as a steroid sparing agent however the develop-
ment of severe arthralgia, joint stiffness, rash, and fever
with a CRP of 164 mg/L led to its withdrawal after 9 days.
Mycophenolate mofetil (1 g BD) was substituted however
CT scan of pelvis indicating multiple enlarged lymph nodes Figure 2
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despite 3 months treatment; prednisolone dose could not
be reduced below 50 mg/day.
Given the unresponsiveness of this patient's disease to a
number of immunosuppressant drugs, and reports of a
beneficial response in refractory AOSD [2], a trial of ana-
kinra, (100 mg/day) was commenced. Within 24 hours
there was almost complete resolution of symptoms. CRP
normalized within 7 days. The patient has remained on
anakinra therapy for 16 months with continued symptom
control. Temporary interruption of treatment on two
occasions was associated with recurrence of rash, fever
and arthralgia within 24 hours. Symptoms quickly
resolved on recommencing anakinra. In light of the clini-
Lymph node biopsy demonstrates widespread infiltration by plasma cells Figure 3
Lymph node biopsy demonstrates widespread infiltration by plasma cells.
Table 1: Diagnostic Criteria for Schnitzler Syndrome*
Urticarial skin rash, monoclonal IgM component, and at least 2 of the following criteria:
Fever
Arthralgia or arthritis
Bone pain
Lymphadenopathy
Hepato- and/or splenomegaly
Elevated ESR
Leucocytosis
Abnormal findings on bone morphological investigations
*Another cause must be eliminated in all cases, most notably hyper IgD syndrome, AOSD, hypocomplementaemic urticarial vasculitis, acquired C1 
inhibitor deficiency, and cryoglobulinaemia.Cases Journal 2008, 1:348 http://www.casesjournal.com/content/1/1/348
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cal course and following an extensive literature review, the
final diagnosis of SS was made. The patient fulfilled both
essential criteria and 6 of the additional criteria estab-
lished by Lipsker et al (Table 1) [3].
Discussion
SS is an uncommon syndrome with only 94 cases
reported in the literature [4]. It was first described by L.
Schnitzler [5], as a clinical entity consisting of chronic
urticaria, fever, bone pain, arthralgia or arthritis, and a
monoclonal IgM gammopathy.
This patient was at first thought to have CIU but failed to
respond to conventional therapy. The subsequent devel-
opment of systemic symptoms led to a wide differential
being considered and several specialists reviewed his case.
Because of the prominence of joint symptoms, AOSD was
the provisional diagnosis for some time. It is important to
note that the patient met the diagnostic criteria for AOSD
established by Yamaguchi et al and that these are not
therefore entirely specific and potential remains for diag-
nostic confusion between the two conditions [6]. Specific
diagnostic tests do not exist for either AOSD or SS, how-
ever serum ferritin levels detected in AOSD are usually
higher than in this patient and the presence of a parapro-
tein (typically IgM kappa) is characteristic of SS. Skin,
lymph node and bone marrow biopsies in SS often show
non specific 'reactive changes' on histopathology.
SS is a rare chronic condition and there are no reports of
spontaneous remission [3]. The mean age of onset is 51
years, diagnostic delay is common and greater than 5
years in most cases [3]. In the recent review of 94 pub-
lished cases, the prognosis was regarded as favorable with
91% survival after 15 years [4]. A significant long term
complication (15%) remains the development of lym-
phoproliferative disease, especially Waldenstroms mac-
roglobulinaemia 10–20 years following the onset of
symptoms [3,4]. 3 patients developed amyloidosis in that
series [4].
Chronic urticaria, unresponsive to antihistamines is char-
acteristic of SS and is an important clinical message of this
case. Oral steroids have not been beneficial at acceptable
doses, and given the chronicity of the disease, are associ-
ated with significant cumulative side effects [4]. Despite
the significant evidence of inflammation in this condi-
tion, there is almost complete failure to respond to a vari-
ety of immunosuppressants including azathioprine,
ciclosporin, methotrexate, high dose immunoglobulin,
hydroxychloroquine, dapsone, colchicine, rituximab,
mycophenolate and infliximab [7-10]. Until recently,
therefore, treatment of SS has been associated with a very
disappointing outcome.
Recently, anakinra, an IL-1 receptor antagonist has been
associated with an excellent outcome [7-10]. Within 24
hours of commencing anakinra, our patient had almost
complete resolution of his symptoms, and has since been
able to return to work full time. Discontinuation of anak-
inra for 1 day, on two occasions, was associated with a
rapid disabling return of symptoms.
Six patients with SS have to date made a complete
response, both symptomatically, and with a reduction in
inflammatory markers and white cell count, to anakinra
[7-10]. The longest published follow up is 18 months, our
patient has been treated for 21 months and continues to
require therapy. No patient has to our knowledge discon-
tinued anakinra and remained in remission. It therefore
appears likely that long term treatment will be required,
however periodic withdrawal of therapy seems reasonable
to assess current disease activity.
Anakinra has been well tolerated, with no significant side
effects in either our patient or other cases of SS reported to
date. One patient developed a mild reaction at the injec-
tion site which resolved after few weeks [8], and one
patient had an injection associated headache [10], which
subsided with ongoing therapy.
The pathogenesis of SS is essentially unknown. The
reported universal response to anakinra suggests a key role
of IL-1 in the pathophysiology.
Interestingly, anakinra has also been reported to provide
beneficial effects in patients with Muckle Wells syndrome
[11]. Given that there is also considerable overlap in the
clinical features of SS and Muckle Wells syndrome, this
raises the possibility of common pathophysiology. One
published case of SS had molecular analysis carried out
for mutations in the coding region of NALP3 (the defect
associated with Muckle Wells syndrome), but no muta-
tions were identified [7]. With increasing recognition and
characterization of patients with SS, the possibility that it
forms part of the spectrum of cryopyrin diseases remains.
Conclusion
SS is a rare cause of a common symptom (urticaria), but
this typically occurs in patients with other systemic symp-
toms. These systemic symptoms show considerable over-
lap with AOSD and therefore immunologists,
dermatologists and rheumatologists all need to be aware
of this potential diagnosis. The presence of an IgM parap-
rotein is an important indicator in favour of a diagnosis of
SS.
Patients with SS have a significant risk of late malignancy
and should be carefully monitored for its development.
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ever the introduction of anakinra has been very effective
in this and 4 other published cases. Our experience sug-
gests that treatment with anakinra is likely to be required
in the long term in order to control symptoms, reduce
inflammation and diminish the risk of long term side
effects.
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